Target Name: MIR3920
NCBI ID: G100500823
Review Report on MIR3920 Target / Biomarker Content of Review Report on MIR3920 Target / Biomarker
MIR3920
Other Name(s): microRNA 3920 | hsa-mir-3920 | MicroRNA 3920 | hsa-miR-3920

MIR3920: A Potential Drug Target and Biomarker

Molecular Intelligence (MOI) has identified a potential drug target and biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. The target, MIR3920, is a protein that is expressed in various tissues and cells throughout the body. It is involved in multiple cellular processes, including cell signaling, cell adhesion, and chromatin regulation. In this article, we will discuss the discovery of MIR3920 as a potential drug target and biomarker, its function in disease, and its potential as a therapeutic approach.

The Protein MIR3920

MIR3920 is a 21-kDa transmembrane protein that is expressed in various tissues and cells, including brain, heart, liver, and muscle. It is characterized by a N-terminal extracellular domain, a transmembrane region, and a C-terminal intracellular domain. The C-terminal domain is known to contain a potential drug target, the MIR3920-ASP2 region.

The MIR3920-ASP2 region is a unique domain that contains a conserved Asp2 residue and a Glu3 residue. The Asp2 residue is known to play a role in protein-protein interactions and can modulate the activity of various cellular signaling pathways. The Glu3 residue is known to be involved in the regulation of cellular signaling pathways, including the production of reactive oxygen species (ROS) that can contribute to oxidative stress and inflammation.

MIR3920's Interaction with other Proteins

MIR3920 has been shown to interact with various proteins, including the transcription factor, p53. The p53 protein is a well-known tumor suppressor that plays a critical role in the regulation of cellular signaling pathways. MIR3920 has been shown to physically interact with p53 and can modulate its activity.

Additionally, MIR3920 has been shown to interact with the protein, TP53. TP53 is a tumor suppressor gene that is often mutated in various types of cancer. MIR3920 has been shown to physically interact with TP53 and can modulate its activity, which may have implications for the regulation of cellular signaling pathways and the development of cancer.

MIR3920's Role in Disease

MIR3920 has been shown to be involved in multiple cellular processes that are involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and metabolic disorders.

MIR3920 has been shown to be involved in the regulation of cell signaling pathways, including the regulation of angiogenesis, which is the process by which new blood vessels are formed. MIR3920 has been shown to be involved in the regulation of theNotch signaling pathway, which is involved in the regulation of cellular signaling pathways that contribute to the development of cancer.

MIR3920 has also been shown to be involved in the regulation of cellular apoptosis, which is the process by which cells die naturally in response to various stimuli, including those that are harmful to the cell. MIR3920 has been shown to play a role in the regulation of apoptosis by modulating the activity of the protein, Bcl-2.

MIR3920 has also been shown to be involved in the regulation of cellular immigration, which is the process by which cells move from the cell body to the plasma membrane. MIR3920 has been shown to play a role in the regulation of

Protein Name: MicroRNA 3920

The "MIR3920 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR3920 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR3921 | MIR3922 | MIR3923 | MIR3924 | MIR3925 | MIR3926-1 | MIR3926-2 | MIR3927 | MIR3928 | MIR3929 | MIR3934 | MIR3935 | MIR3936 | MIR3936HG | MIR3937 | MIR3938 | MIR3939 | MIR3940 | MIR3941 | MIR3942 | MIR3943 | MIR3944 | MIR3945 | MIR3945HG | MIR3960 | MIR3972 | MIR3973 | MIR3974 | MIR3976 | MIR3976HG | MIR3977 | MIR3978 | MIR409 | MIR410 | MIR411 | MIR412 | MIR421 | MIR422A | MIR423 | MIR424 | MIR425 | MIR4251 | MIR4252 | MIR4253 | MIR4254 | MIR4255 | MIR4256 | MIR4257 | MIR4258 | MIR4259 | MIR4260 | MIR4261 | MIR4262 | MIR4263 | MIR4264 | MIR4265 | MIR4266 | MIR4267 | MIR4268 | MIR4269 | MIR4270 | MIR4271 | MIR4272 | MIR4273 | MIR4274 | MIR4275 | MIR4276 | MIR4277 | MIR4278 | MIR4279 | MIR4280 | MIR4281 | MIR4282 | MIR4283-1 | MIR4283-2 | MIR4284 | MIR4285 | MIR4286 | MIR4287 | MIR4288 | MIR4289 | MIR429 | MIR4290 | MIR4291 | MIR4292 | MIR4293 | MIR4294 | MIR4295 | MIR4296 | MIR4297 | MIR4298 | MIR4299 | MIR4300 | MIR4300HG | MIR4301 | MIR4302 | MIR4303 | MIR4304 | MIR4305 | MIR4306